172 related articles for article (PubMed ID: 30300821)
1. NF-κB signaling activation via increases in BRD2 and BRD4 confers resistance to the bromodomain inhibitor I-BET151 in U937 cells.
Hishiki K; Akiyama M; Kanegae Y; Ozaki K; Ohta M; Tsuchitani E; Kaito K; Yamada H
Leuk Res; 2018 Nov; 74():57-63. PubMed ID: 30300821
[TBL] [Abstract][Full Text] [Related]
2. BET bromodomain proteins are required for glioblastoma cell proliferation.
Pastori C; Daniel M; Penas C; Volmar CH; Johnstone AL; Brothers SP; Graham RM; Allen B; Sarkaria JN; Komotar RJ; Wahlestedt C; Ayad NG
Epigenetics; 2014 Apr; 9(4):611-20. PubMed ID: 24496381
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological targeting of BET proteins inhibits renal fibroblast activation and alleviates renal fibrosis.
Xiong C; Masucci MV; Zhou X; Liu N; Zang X; Tolbert E; Zhao TC; Zhuang S
Oncotarget; 2016 Oct; 7(43):69291-69308. PubMed ID: 27732564
[TBL] [Abstract][Full Text] [Related]
4. The BET bromodomain inhibitor I-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers.
Long J; Li B; Rodriguez-Blanco J; Pastori C; Volmar CH; Wahlestedt C; Capobianco A; Bai F; Pei XH; Ayad NG; Robbins DJ
J Biol Chem; 2014 Dec; 289(51):35494-502. PubMed ID: 25355313
[TBL] [Abstract][Full Text] [Related]
5. I-BET151 suppresses osteoclast formation and inflammatory cytokines secretion by targetting BRD4 in multiple myeloma.
Guo NH; Zheng JF; Zi FM; Cheng J
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30455393
[No Abstract] [Full Text] [Related]
6. The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts.
Klein K; Kabala PA; Grabiec AM; Gay RE; Kolling C; Lin LL; Gay S; Tak PP; Prinjha RK; Ospelt C; Reedquist KA
Ann Rheum Dis; 2016 Feb; 75(2):422-9. PubMed ID: 25467295
[TBL] [Abstract][Full Text] [Related]
7. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism.
Boehm D; Calvanese V; Dar RD; Xing S; Schroeder S; Martins L; Aull K; Li PC; Planelles V; Bradner JE; Zhou MM; Siliciano RF; Weinberger L; Verdin E; Ott M
Cell Cycle; 2013 Feb; 12(3):452-62. PubMed ID: 23255218
[TBL] [Abstract][Full Text] [Related]
8. Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151.
Gallagher SJ; Mijatov B; Gunatilake D; Gowrishankar K; Tiffen J; James W; Jin L; Pupo G; Cullinane C; McArthur GA; Tummino PJ; Rizos H; Hersey P
Pigment Cell Melanoma Res; 2014 Nov; 27(6):1126-37. PubMed ID: 24924589
[TBL] [Abstract][Full Text] [Related]
9. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.
Pastori C; Kapranov P; Penas C; Peschansky V; Volmar CH; Sarkaria JN; Bregy A; Komotar R; St Laurent G; Ayad NG; Wahlestedt C
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8326-31. PubMed ID: 26111795
[TBL] [Abstract][Full Text] [Related]
10. Bromodomain and extra-terminal domain bromodomain inhibition prevents synovial inflammation via blocking IκB kinase-dependent NF-κB activation in rheumatoid fibroblast-like synoviocytes.
Xiao Y; Liang L; Huang M; Qiu Q; Zeng S; Shi M; Zou Y; Ye Y; Yang X; Xu H
Rheumatology (Oxford); 2016 Jan; 55(1):173-84. PubMed ID: 26324948
[TBL] [Abstract][Full Text] [Related]
11. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
[TBL] [Abstract][Full Text] [Related]
12. BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity.
Khoueiry P; Ward Gahlawat A; Petretich M; Michon AM; Simola D; Lam E; Furlong EE; Benes V; Dawson MA; Prinjha RK; Drewes G; Grandi P
Epigenetics Chromatin; 2019 Jul; 12(1):39. PubMed ID: 31266503
[TBL] [Abstract][Full Text] [Related]
13. The Brd4 acetyllysine-binding protein is involved in activation of polyomavirus JC.
Wollebo HS; Bellizzi A; Cossari DH; Salkind J; Safak M; White MK
J Neurovirol; 2016 Oct; 22(5):615-625. PubMed ID: 27007123
[TBL] [Abstract][Full Text] [Related]
14. Bromodomain and Extra-terminal (BET) Protein Inhibitors Suppress Chondrocyte Differentiation and Restrain Bone Growth.
Niu N; Shao R; Yan G; Zou W
J Biol Chem; 2016 Dec; 291(52):26647-26657. PubMed ID: 27821592
[TBL] [Abstract][Full Text] [Related]
15. Effects of Celastrol on growth inhibition of U937 leukemia cells through the regulation of the Notch1/NF-kappaB signaling pathway in vitro.
Wang XN; Wu Q; Yang X; Zhang LS; Wu YP; Lu C
Chin J Cancer; 2010 Apr; 29(4):385-90. PubMed ID: 20346213
[TBL] [Abstract][Full Text] [Related]
16. Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors.
Ceribelli M; Kelly PN; Shaffer AL; Wright GW; Xiao W; Yang Y; Mathews Griner LA; Guha R; Shinn P; Keller JM; Liu D; Patel PR; Ferrer M; Joshi S; Nerle S; Sandy P; Normant E; Thomas CJ; Staudt LM
Proc Natl Acad Sci U S A; 2014 Aug; 111(31):11365-70. PubMed ID: 25049379
[TBL] [Abstract][Full Text] [Related]
17. Anticancer Effects of I-BET151, an Inhibitor of Bromodomain and Extra-Terminal Domain Proteins.
Lai J; Liu Z; Zhao Y; Ma C; Huang H
Front Oncol; 2021; 11():716830. PubMed ID: 34540687
[TBL] [Abstract][Full Text] [Related]
18. Pan- and Isoform-specific Inhibition of the Bromodomain and Extra-terminal Proteins and Evaluation of Synergistic Potential With Entospletinib in Canine Lymphoma.
Kong W; Sender S; Perez SV; Sekora A; Ruetgen B; Junghanss C; Nolte I; Murua Escobar H
Anticancer Res; 2020 Jul; 40(7):3781-3792. PubMed ID: 32620617
[TBL] [Abstract][Full Text] [Related]
19. Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2.
Liu S; Walker SR; Nelson EA; Cerulli R; Xiang M; Toniolo PA; Qi J; Stone RM; Wadleigh M; Bradner JE; Frank DA
Mol Cancer Ther; 2014 May; 13(5):1194-205. PubMed ID: 24435449
[TBL] [Abstract][Full Text] [Related]
20. Selective Antagonists of the Bronchiolar Epithelial NF-κB-Bromodomain-Containing Protein 4 Pathway in Viral-Induced Airway Inflammation.
Tian B; Liu Z; Yang J; Sun H; Zhao Y; Wakamiya M; Chen H; Rytting E; Zhou J; Brasier AR
Cell Rep; 2018 Apr; 23(4):1138-1151. PubMed ID: 29694891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
